Company intelligence / Profile preview
Treadwell Therapeutics
New York City, New York, United Statestreadwelltx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Treadwell Therapeutics has demonstrated promising early efficacy signals in relapsed/refractory AML with its lead PLK4 inhibitor CFI‑400945 and has advanced CFI‑402257 into Phase I/II trials for ER+/Her2– breast cancer. The company’s pipeline also includes a HPK1 inhibitor and preclinical biologic/TCR-based cell therapy programs. Clinical data to date show tolerable safety profiles and confirmed responses in targeted indications.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesBiologicsT-cell receptor (TCR)-based cell therapies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical partnerships disclosed; seeking partners for further development of certain assets.
Beyond the preview
Go deeper on Treadwell Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Treadwell Therapeutics.